Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Edoxaban (INN, codenamed DU-176b) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. In animal studies, edoxaban is potent, selective for factor Xa and has good oral bioavailability, but it has not been approved for use in humans.
Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008). "DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles". Journal of Thrombosis and Haemostasis : JTH. 6 (9): 1542–9. doi:10.1111/j.1538-7836.2008.03064.x. PMID18624979. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Sobieraj-Teague M, O'Donnell M, Eikelboom J (2009). "New anticoagulants for atrial fibrillation". Seminars in Thrombosis and Hemostasis. 35 (5): 515–24. doi:10.1055/s-0029-1234147. PMID19739042. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
